Literature DB >> 6199788

Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.

L E Rasmussen, R M Nelson, D C Kelsall, T C Merigan.   

Abstract

Murine monoclonal antibodies to human cytomegalovirus (CMV) strain AD169 were selected that neutralized virus infectivity. One monoclonal antibody-producing hybridoma, 1G6, was used to produce ascites fluid from which immunoglobulin was isolated. This antibody efficiently neutralized CMV AD169, other laboratory strains (Towne, Davis), and clinical isolates of CMV in early tissue culture passage (less than 10) in the absence of complement. The antibody immunoprecipitated a single 86,000-dalton protein from both laboratory and clinical strains. This viral protein was demonstrated by indirect immunofluorescence to be localized in the cytoplasm of CMV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199788      PMCID: PMC344941          DOI: 10.1073/pnas.81.3.876

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity.

Authors:  W A Volk; R M Synder; D C Benjamin; R R Wagner
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

2.  Effect of monoclonal antibodies on limited proteolysis of native glycoprotein gD of herpes simplex virus type 1.

Authors:  R J Eisenberg; D Long; L Pereira; B Hampar; M Zweig; G H Cohen
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

3.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

4.  Location of the structural genes for glycoproteins gD and gE and for other polypeptides in the S component of herpes simplex virus type 1 DNA.

Authors:  G T Lee; M F Para; P G Spear
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

5.  Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and preliminary use in diagnosis of cytomegalovirus pneumonia.

Authors:  L C Goldstein; J McDougall; R Hackman; J D Meyers; E D Thomas; R C Nowinski
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

6.  Comparative structural analysis of glycoprotein gD of herpes simplex virus types 1 and 2.

Authors:  R J Eisenberg; M Ponce de Leon; G H Cohen
Journal:  J Virol       Date:  1980-08       Impact factor: 5.103

7.  Electrophoretic analysis of polypeptides immune precipitated from cytomegalovirus-infected cell extracts by human sera.

Authors:  L Pereira; M Hoffman; N Cremer
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

8.  Glycoprotein gE of herpes simplex virus type 1: effects of anti-gE on virion infectivity and on virus-induced fc-binding receptors.

Authors:  M F Para; R B Baucke; P G Spear
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

9.  Monoclonal antibodies to human cytomegalovirus: three surface membrane proteins with unique immunological and electrophoretic properties specify cross-reactive determinants.

Authors:  L Pereira; M Hoffman; D Gallo; N Cremer
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

10.  Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus.

Authors:  L Rasmussen; D Kelsall; R Nelson; W Carney; M Hirsch; D Winston; J Preiksaitis; T C Merigan
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

View more
  44 in total

1.  Distinct glycoprotein O complexes arise in a post-Golgi compartment of cytomegalovirus-infected cells.

Authors:  Regan N Theiler; Teresa Compton
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus.

Authors:  S Keay; T C Merigan; L Rasmussen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates.

Authors:  Lucy Rasmussen; Aimee Geissler; Catherine Cowan; Amanda Chase; Mark Winters
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus.

Authors:  D R Gretch; B Kari; L Rasmussen; R C Gehrz; M F Stinski
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

5.  Human immune responses to major human cytomegalovirus glycoprotein complexes.

Authors:  Y N Liu; B Kari; R C Gehrz
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

6.  Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion.

Authors:  Eric R Kinzler; Teresa Compton
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites.

Authors:  J A Simpson; J C Chow; J Baker; N Avdalovic; S Yuan; D Au; M S Co; M Vasquez; W J Britt; K L Coelingh
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Identification and characterization of the guinea-pig cytomegalovirus glycoprotein H gene.

Authors:  R C Brady; M R Schleiss
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration.

Authors:  A O Fuller; R E Santos; P G Spear
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

10.  Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding.

Authors:  M A Billstrom; W J Britt
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.